Parkinson’s disease therapy: what lies ahead? | Journal of...
non-ergot dopamine agonists, inhibitors of the monoamine oxidase B or, less frequently, amantadine or anticholinergics. Treatment is then tailored to the severity of the symptoms, age, and pre-existing conditions